United States v. Gazelle Craig

CourtCourt of Appeals for the Fifth Circuit
DecidedAugust 4, 2020
Docket18-20671
StatusUnpublished

This text of United States v. Gazelle Craig (United States v. Gazelle Craig) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Gazelle Craig, (5th Cir. 2020).

Opinion

Case: 18-20671 Document: 00515514219 Page: 1 Date Filed: 08/04/2020

IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT United States Court of Appeals Fifth Circuit

No. 18-20671 FILED August 4, 2020 Lyle W. Cayce UNITED STATES OF AMERICA, Clerk

Plaintiff - Appellee

v.

GAZELLE CRAIG, D.O.; SHANE FAITHFUL,

Defendants - Appellants

Appeals from the United States District Court for the Southern District of Texas USDC No. 4:17-CR-419-1 USDC No. 4:17-CR-419-2

Before BARKSDALE, HAYNES, and WILLETT, Circuit Judges. PER CURIAM:* Primarily at issue are Gazelle Craig’s and Shane Faithful’s challenges to: the sufficiency of the evidence supporting their jury-trial convictions for conspiring to unlawfully distribute controlled substances, in violation of 21 U.S.C. §§ 841(a)(1) and 846, and aiding and abetting the unlawful distribution of controlled substances, or unlawfully distributing controlled substances

* Pursuant to 5th Cir. R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5th Cir. R. 47.5.4. Case: 18-20671 Document: 00515514219 Page: 2 Date Filed: 08/04/2020

No. 18-20671 having been aided or abetted by others, in violation of 18 U.S.C. § 2 and 21 U.S.C. § 841(a)(1); and the district court’s excusing a juror, rather than declaring a mistrial, after that juror had contact with a Government agent during the evening following the seventh day of a nine-day retrial. Appellants also claim additional trial and sentencing errors. Of the 11 issues appellants raise, nine of them, including sufficiency-of-the-evidence challenges, are reviewed only for plain error. The only two fully preserved issues are Craig’s challenges to the procedural and substantive reasonableness of her sentence. AFFIRMED IN PART; VACATED and REMANDED IN PART. I. Appellants began operating the Gulfton Community Health Center (Gulfton) in Houston, Texas, as a pain-management clinic in 2015. Craig was Gulfton’s medical director and sole treating physician; Faithful, its administrator and owner of its management company. They split the clinic’s profits. As stated in Faithful’s opening brief on appeal: The clinic’s “formulary”—the “certain group of drugs” Dr. Craig consistently prescribed for treatment—consisted of “Norco,” a mixture of the opioid hydrocodone and acetaminophen[,] . . . and “Soma,” a brand of the drug carisoprodol marketed as a muscle relaxant. Both hydrocodone ([S]chedule II) and carisoprodol ([S]chedule IV) are federally controlled substances, meaning the only way to legally obtain them is through a prescription issued by a practitioner registered with the Drug Enforcement Agency (DEA).

The Texas State Medical Board began a formal investigation in September 2015 of Craig’s practice at Gulfton based on allegations it was “an illegal pain clinic”. As a result, the Board filed a complaint against Craig in August 2016 alleging, inter alia, she failed to prescribe controlled substances to patients in a manner consistent with public health and welfare.

2 Case: 18-20671 Document: 00515514219 Page: 3 Date Filed: 08/04/2020

No. 18-20671 In addition, the DEA investigated Gulfton for operating as a “pill mill”: “a drug business exchanging controlled substances for cash under the guise of a doctor’s office”. United States v. Oti, 872 F.3d 678, 685 (5th Cir. 2017). The Government’s brief on appeal detailed Gulfton’s business model as follows: Facilitators[, defined infra,] recruited putative patients off the streets, offering them cash—and sometimes breakfast and a beer—to go to Gulfton, pay the clinic fee [averaging, according to appellants’ presentence investigation reports (PSR), $300 per visit] using the facilitator’s money, fill out intake forms, undergo a pro forma medical exam, and obtain from Craig a prescription for a drug combination known as the “Vegas cocktail.” That cocktail consisted of hydrocodone, an opioid listed as a Schedule II controlled substance because of its potential for abuse; and carisoprodol, a muscle relaxant listed on Schedule IV that increases the euphoric high of the opioid. Once patients had the prescriptions, the facilitator took the patient to a pharmacy to have the prescription filled, after which the patient would hand the unopened bottles of pills to the facilitator in exchange for cash.

The facilitators, also known as “crew leaders”, were drug dealers who accounted for at least 75 percent of the clinic’s business. As part of this business model, Gulfton required advance cash payments; it did not accept credit-card payments or insurance coverage. In that regard, Faithful: determined the prescriptions’ prices; required patients, rather than facilitators, pay for the prescriptions; and prohibited patients and facilitators from exchanging money inside the clinic. Faithful also: prohibited from the clinic cell phones, other electronic devices, and bags; and required physician assistants to pat down patients to ensure they were not carrying an item that could record Gulfton’s operations. If a patient violated Gulfton’s policies, Craig denied that patient a prescription or prescribed a lower number of pills. When that occurred, facilitators could substitute another individual for the patient denied a 3 Case: 18-20671 Document: 00515514219 Page: 4 Date Filed: 08/04/2020

No. 18-20671 prescription or receive a Gulfton business card that served as a clinic credit. Each credit, approved by Craig or Faithful, allowed a facilitator to bring another patient to the clinic without paying in full for his prescription. To help anticipate the number of patients to be seen each day, the clinic’s appointment book detailed the names of the facilitators, and their expected number of patients, arriving the following day. According to DEA analysis of records kept by the Texas State Board of Pharmacy, from 1 March 2015 to 15 June 2017 Craig issued 18,253 prescriptions for hydrocodone and 15,649 prescriptions for carisoprodol. Moreover, those 33,902 prescriptions accounted for 98.6 percent of all prescriptions she wrote during that time. Gulfton’s last day of operations was 7 July 2017. The clinic saw 66 patients that day, to whom Dr. Craig prescribed 7,460 hydrocodone pills and 5,565 carisoprodol pills. Prescriptions for those 13,025 pills netted both appellants single-day cash earnings of $5,720. On 10 July, DEA and local agents executed a search warrant at the clinic and search and arrest warrants at appellants’ residences, arresting both Craig and Faithful. At Faithful’s residence, agents found, inter alia, an appointment card given as clinic credit and over $141,000 cash in envelopes labeled “Shane” and “Doc”. At Craig’s residence, agents found, inter alia, over $39,000 cash in envelopes labeled “Doc” or “Dr. Craig”. At Gulfton, agents found, inter alia, over $15,500 cash, also in labeled envelopes, and x-ray and magnetic resonance imaging requests, presigned by Dr. Craig, designating chronic lower back pain as a patient’s ailment but leaving blank the information about the patient, including his name. Both Craig and Faithful were indicted on four counts: conspiring to unlawfully distribute and dispense controlled substances “not with a legitimate medical purpose and outside the scope of professional practice”, in 4 Case: 18-20671 Document: 00515514219 Page: 5 Date Filed: 08/04/2020

No. 18-20671 violation of 21 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Zuniga
18 F.3d 1254 (Fifth Circuit, 1994)
United States v. McIntosh
280 F.3d 479 (Fifth Circuit, 2002)
United States v. Smith
354 F.3d 390 (Fifth Circuit, 2003)
United States v. Inman
411 F.3d 591 (Fifth Circuit, 2005)
United States v. Austin
479 F.3d 363 (Fifth Circuit, 2007)
United States v. Maturin
488 F.3d 657 (Fifth Circuit, 2007)
United States v. McDowell
498 F.3d 308 (Fifth Circuit, 2007)
United States v. Cisneros-Gutierrez
517 F.3d 751 (Fifth Circuit, 2008)
United States v. Armstrong
550 F.3d 382 (Fifth Circuit, 2008)
United States v. Brown
553 F.3d 768 (Fifth Circuit, 2008)
United States v. Delgado-Martinez
564 F.3d 750 (Fifth Circuit, 2009)
Remmer v. United States
350 U.S. 377 (Supreme Court, 1956)
Batson v. Kentucky
476 U.S. 79 (Supreme Court, 1986)
Richardson v. Marsh
481 U.S. 200 (Supreme Court, 1987)
Georgia v. McCollum
505 U.S. 42 (Supreme Court, 1992)
Gall v. United States
552 U.S. 38 (Supreme Court, 2007)
Puckett v. United States
556 U.S. 129 (Supreme Court, 2009)
United States v. Guillermo Balleza
613 F.3d 432 (Fifth Circuit, 2010)
United States v. Gonzalez-Rodriguez
621 F.3d 354 (Fifth Circuit, 2010)
United States v. Henry Thomas Leigh, M.D.
487 F.2d 206 (Fifth Circuit, 1974)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. Gazelle Craig, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-gazelle-craig-ca5-2020.